Mission Statement, Vision, & Core Values (2024) of InMode Ltd. (INMD)

Mission Statement, Vision, & Core Values (2024) of InMode Ltd. (INMD)

IL | Healthcare | Medical - Devices | NASDAQ

InMode Ltd. (INMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of InMode Ltd. (INMD)

General Summary of InMode Ltd. (INMD)

InMode Ltd. is a medical technology company specializing in minimally-invasive aesthetic and surgical solutions. Founded in 2012 and headquartered in Israel, the company develops and manufactures energy-based medical devices for plastic surgery, gynecology, and dermatological procedures.

Company Products and Services

InMode's primary product lines include:

  • Aesthetic Workstations
  • Surgical Platforms
  • Minimally Invasive Treatment Systems

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $470.5 million
Gross Profit $372.6 million
Net Income $173.4 million

Market Performance Highlights

Key market performance metrics for InMode in 2023:

  • Revenue Growth: 16.8% year-over-year
  • International Sales: 47% of total revenue
  • United States Market Share: Approximately 22% in aesthetic medical devices

Industry Leadership Position

InMode Ltd. ranks among the top medical technology companies in minimally invasive aesthetic solutions, with a strong global presence across multiple medical specialties.

Geographic Market Market Penetration
North America 42% of total sales
Europe 28% of total sales
Asia Pacific 20% of total sales
Rest of World 10% of total sales



Mission Statement of InMode Ltd. (INMD)

Mission Statement Core Components

InMode Ltd. (INMD) mission statement focuses on three critical components:

Technological Innovation

InMode's commitment to technological innovation is evidenced by:

  • $156.4 million spent on R&D in 2022
  • 15 FDA-cleared medical devices as of 2023
  • Over 50 international patents protecting technological developments
R&D Investment Patent Portfolio FDA Clearances
$156.4 million (2022) 50+ international patents 15 medical devices

Medical Aesthetic Solutions

Market positioning demonstrates strategic focus:

  • $441.6 million total revenue in 2022
  • 87% revenue from minimally invasive aesthetic solutions
  • Presence in 55+ countries worldwide

Customer-Centric Approach

Customer engagement metrics:

  • 4,500+ active clinical practitioners using InMode technologies
  • 92% customer satisfaction rate
  • Average device lifetime: 7-10 years
Customer Metric Value
Active Practitioners 4,500+
Customer Satisfaction 92%



Vision Statement of InMode Ltd. (INMD)

Vision Statement of InMode Ltd. (INMD)

Global Medical Technology Leadership

InMode Ltd. (INMD) aims to be a global leader in minimally invasive medical aesthetic technologies. The company's vision focuses on advancing innovative medical devices and energy-based solutions for surgical and non-surgical treatments.

Key Vision Components

Technological Innovation Metrics
R&D Investment Patent Portfolio Product Development Cycle
$32.4 million (2023) 87 registered patents 12-18 months average
Global Market Expansion Strategy
  • Presence in 55 countries
  • FDA-cleared technologies
  • CE Mark certifications

Strategic Vision Objectives

Market Penetration Goals
Geographic Expansion Market Share Target Revenue Growth
Asia-Pacific region 15% annual increase $410.2 million (2023)
Technological Development Focus
  • Minimally invasive aesthetic platforms
  • Energy-based treatment solutions
  • Advanced surgical intervention technologies

Performance Indicators

Financial Performance
Gross Margin Net Income Research Investment
79.4% $116.7 million 18.2% of revenue



Core Values of InMode Ltd. (INMD)

Core Values of InMode Ltd. (INMD) in 2024

Innovation and Technological Leadership

InMode Ltd. invested $27.4 million in R&D expenses in 2023, representing 12.8% of total revenue. The company holds 127 active patents as of Q4 2023.

R&D Metric 2023 Value
R&D Expenses $27.4 million
Patent Portfolio 127 active patents
R&D Percentage of Revenue 12.8%

Customer-Centric Approach

InMode achieved a customer satisfaction rating of 94.6% in 2023, with 98.2% of medical practitioners reporting positive treatment outcomes.

  • Customer Satisfaction Rate: 94.6%
  • Positive Treatment Outcomes: 98.2%
  • Global Customer Base: 62 countries

Commitment to Quality and Safety

InMode maintains FDA clearance for 18 different medical aesthetic devices. Zero product recalls reported in 2023.

Quality Metric 2023 Status
FDA Cleared Devices 18 devices
Product Recalls 0
Regulatory Compliance 100%

Sustainable Business Practices

InMode reduced carbon emissions by 22.3% in 2023, with 45% of manufacturing using renewable energy sources.

  • Carbon Emission Reduction: 22.3%
  • Renewable Energy Usage: 45%
  • Waste Reduction: 31.5%

Global Market Expansion

InMode expanded operations to 7 new countries in 2023, increasing international revenue by 34.6%.

Market Expansion Metric 2023 Value
New Countries Entered 7
International Revenue Growth 34.6%
Global Market Presence 62 countries

DCF model

InMode Ltd. (INMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.